# A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer

> **NCT02439450** · PHASE1,PHASE2 · COMPLETED · sponsor: **Heat Biologics** · enrollment: 121 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** Viagenpumatucel-L
- **DRUG:** Nivolumab
- **DRUG:** Pembrolizumab
- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT02439450
- **Lead sponsor:** Heat Biologics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-15
- **Primary completion:** 2021-05-03
- **Final completion:** 2022-11-04
- **Target enrollment:** 121 (ACTUAL)
- **Last updated:** 2023-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02439450

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02439450, "A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02439450. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*